In the open-label phase 3 trial CheckMate, 227 previously untreated patients with stage IV or recurrent NSCLC and a PD-L1 TPS of at least 1% were randomly assigned to receive Nivolumab plus Ipilimumab or Nivolumab alone or chemotherapy; those with a PD-L1 expression < 1% were randomly assigned to Nivolumab plus Ipilimumab or Nivolumab plus chemotherapy or chemotherapy alone. The gene discussed is CD274; the disease is non-small cell lung carcinoma.